Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Virginia M. Klimek; Emily K. Dolezal; Michael T. Tees; Sean M. Devlin; Karen Stein; Alejandro Romero; Stephen D. Nimer

doi:10.1016/j.leukres.2012.04.025

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Virginia M. Klimek, Emily K. Dolezal, Michael T. Tees, Sean M. Devlin, Karen Stein, Alejandro Romero, Stephen D. Nimer

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

Original language	English (US)
Pages (from-to)	1093-1097
Number of pages	5
Journal	Leukemia Research
Volume	36
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2012.04.025
State	Published - Sep 1 2012
Externally published	Yes

Keywords

5-Azacytidine
Decitabine
Leukemia
Therapy-related cancer

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2012.04.025

Fingerprint Dive into the research topics of 'Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this

@article{35543150afb44488b91af3d6d99a618c,

title = "Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes",

abstract = "We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.",

keywords = "5-Azacytidine, Decitabine, Leukemia, Therapy-related cancer",

author = "Klimek, {Virginia M.} and Dolezal, {Emily K.} and Tees, {Michael T.} and Devlin, {Sean M.} and Karen Stein and Alejandro Romero and Nimer, {Stephen D.}",

year = "2012",

month = sep,

day = "1",

doi = "10.1016/j.leukres.2012.04.025",

language = "English (US)",

volume = "36",

pages = "1093--1097",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

AU - Klimek, Virginia M.

AU - Dolezal, Emily K.

AU - Tees, Michael T.

AU - Devlin, Sean M.

AU - Stein, Karen

AU - Romero, Alejandro

AU - Nimer, Stephen D.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

AB - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

KW - 5-Azacytidine

KW - Decitabine

KW - Leukemia

KW - Therapy-related cancer

UR - http://www.scopus.com/inward/record.url?scp=84864008372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864008372&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.04.025

DO - 10.1016/j.leukres.2012.04.025

M3 - Article

C2 - 22608310

AN - SCOPUS:84864008372

VL - 36

SP - 1093

EP - 1097

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -